Hernix 40mg (neratinib)

Niratinib is an oral, irreversible tyrosine kinase inhibitor. It is the only product in the world approved for intensive adjuvant therapy after treatment with HER2-positive breast cancer with trastuzumab (Herceptin) to reduce the risk of recurrence. The applicable population is to complete the standard trastuzumab adjuvant treatment of patients with undeveloped disease but high risk factors.